Handelsavisen
prelaunch
Companies ›Healthcare ›CALC
CA
CALC — Nasdaq Pharmaceuticals

CalciMedica, Inc.

$0,83
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
13,6M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
-450,7 %
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$0,84
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About

CalciMedica, Inc. is a clinical-stage pharmaceutical company developing therapies for rare diseases, currently funded through equity offerings and debt facilities rather than product revenue.

Business. CalciMedica, Inc. (Nasdaq: CALC) is a pharmaceutical company operating within the Healthcare sector. The firm focuses on the development and commercialization of pharmaceutical products, with its business activities centered on product sales. Specific details regarding operating segments and geographic revenue mix are not disclosed in the available data. The company is headquartered in the United States and is primarily listed on the Nasdaq stock exchange.

Classification93 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
Industry groupPharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY3 analysts
2 buy1 hold0 sell
Avg 12m price target10,50

Analyst recommendations

3 analysts · consensus Buy
Buy2
Hold1
Sell0
12-month price target
10,50
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
3 analysts · indicative
Ownership→
Vanguard Capital Management, LLC
largest disclosed fund holder
Profitability→
-450,7 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning CALC.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to CALC. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    CalciMedica, Inc. (Nasdaq: CALC) is a pharmaceutical company operating within the Healthcare sector. The firm focuses on the development and commercialization of pharmaceutical products, with its business activities centered on product sales. Specific details regarding operating segments and geographic revenue mix are not disclosed in the available data. The company is headquartered in the United States and is primarily listed on the Nasdaq stock exchange.

    Classification93 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    Industry groupPharmaceuticals
    AI synthesis
    GENERATED

    CalciMedica maintains a negative equity position of -$1.1 million against total liabilities of $9.7 million, resulting in a debt-to-equity ratio of -0.0 and a return on equity of -4.51%. The balance sheet holds $8.2 million in cash and equivalents, providing a current ratio of 1.61. Operating cash flow stands at -$4.9 million for the period, with free cash flow matching this outflow due to zero capital expenditures. The market capitalization is $15.9 million, yielding a price-to-earnings ratio of 3.19 based on a net income of $5.0 million, though this metric is distorted by non-operating items given the -$5.6 million operating loss.

    Profitability metrics reflect a pre-commercial development stage. The company reports a net income of $4.9 million despite an operating loss of $5.6 million, indicating significant non-operating gains or accounting adjustments. Return on assets is 0.58%, which is typical for early-stage biotechs with minimal asset bases relative to cash holdings. The negative EV/EBITDA of -1.38 underscores the absence of sustainable earnings before interest, taxes, depreciation, and amortization.

    Revenue concentration data is absent from the provided segments and geography sections, implying no material product revenue streams. The company’s financial profile is driven entirely by financing activities and R&D expenditures rather than commercial sales.

    Growth trajectory analysis is limited by the absence of historical period data in the input. However, the share count has expanded from 13.5 million to 15.7 million basic shares, reflecting recent capital raises. The diluted share count of 16.3 million indicates moderate dilution pressure from warrants and options.

    Risk assessment flags high liquidity and high dilution risks. Filings reference going-concern or substantial-doubt language, citing the need for additional capital to continue operations. The diluted share count is moderately above the basic share count, and source documents mention dilution or offering risk. The company faces imminent listing compliance issues, having closed below $1.00 for 21 consecutive trading days, approaching the 30-day deficiency threshold for Nasdaq Rule 5550(a)(2).

    Recent events include analyst coverage with a mean price target of $10.50 and a mean recommendation of 2.33 (Buy). The company has utilized At-The-Market offerings and private placements to fund operations. Filing observations highlight convertible notes, warrants liabilities, and stock-based compensation expenses. The news event observations confirm the listing compliance warning, with the last close at $0.9401.

    Key takeaways
    • Negative equity of -$1.1 million and high dilution risk due to warrant and option overhang.
    • Imminent Nasdaq listing deficiency risk after 21 consecutive days below $1.00 bid price.
    • Operating loss of $5.6 million offset by non-operating items to yield $4.9 million net income.
    • Cash position of $8.2 million provides limited runway given -$4.9 million operating cash flow.
    • Analyst consensus suggests upside to $10.50, contrasting with current sub-$1.00 trading price.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-03-31
    Q4 2025 · Quarter highlights

    Operating income -$5.6M.

    Revenue—
    Operating income-$5.6M
    Net income$5.0M
    Free cash flow-$4.9M
    EPS—
    Operating cash flow-$4.9M
    Financials
    Income statement
    Revenue—
    Gross profit—
    Operating income-$5.6M
    Net income$5.0M
    Balance sheet
    Total assets$8.6M
    Total liabilities$9.7M
    Total equity-$1.1M
    Cash & equivalents$8.2M
    Long-term debt—
    Cash flow
    Operating cash flow-$4.9M
    CapEx$0.00
    Free cash flow-$4.9M
    SBC$561.0k
    Highlights
    • ▍Operating income -$5.6M

    Valuation FY

    Market price
    $0,83
    Market cap
    $15.9M
    Enterprise valueⓘ
    $7.7M
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    -$1.1M
    Net cashⓘ
    $8.2M
    Current ratioⓘ
    1.6
    Debt / equityⓘ
    —
    ROAⓘ
    57.8%
    ROEⓘ
    -4.5%
    Cash conversionⓘ
    -98.0%
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    3.7%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -0,76
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    3
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    as of 2026-08-02 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPS—no estimate—no estimate-0,76
    Revenue—no estimate—no estimate0 USD
    Operating income—no estimate—no estimate-26,6M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution3 analysts
    Strong buy0
    Buy2
    Hold1
    Sell0
    Strong sell0
    12-month price target$10,50 · Median $10,50
    Low $6,00High $15,00
    Operating income · consensus-26,6M USD
    EPS surprise
    −160,9 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$6,00
    Mean$10,50
    Median$10,50
    High$15,00
    Spot$0,83
    +1157.5 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskHigh
    Liquidity riskHigh
    Filing-based flags
    • Diluted share count is moderately above the basic share count.
    • Filings reference going-concern or substantial-doubt language.
    • Source documents mention dilution or offering risk.

    Benchmarks vs cohort

    ROE-450,7 %Bottom quartile
    D/E-0,00Above P75
    Cash Conv-0,98Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 5 937 sh1 exercises · 2 grants3 insiders
    • Zaytsev EvgenyDirector · Director Stock Option (Right to Buy) → Common StockAcquired 20 000 @ $0,97grant · 2026-07-02
    • Glicklich AlanDirector · Director Stock Option (Right to Buy) → Common StockAcquired 937 @ $3,26grant · 2025-10-13
    • Roberts Eric WDirector, CHIEF BUSINESS OFFICER, 10% owner · Employee Stock Option (Right to Buy) → Common StockDisposed 15 000 @ $1,53exercise · 2025-08-20

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Regulatory filings
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    • Reference data
    How metrics are computed
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Market Cap
      market_price * shares_outstanding_diluted
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    Source documents
    • CalciMedica, Inc. company facts · 2026-08-02
    • CalciMedica, Inc. 10-Q 2026-05-12 · 2026-08-02
    • CalciMedica, Inc. 10-K 2026-03-03 · 2026-08-02
    • CalciMedica, Inc. 10-Q 2025-11-12 · 2026-08-02
    • CalciMedica, Inc. 10-Q 2025-08-12 · 2026-08-02
    • ha_price_listing fired on CALC · 2026-08-02
    • CalciMedica Inc Market data — analyst estimates · 2026-08-02
    • CalciMedica Inc Market data — ESG · 2026-08-02

    Ownership & reference

    Top holders

    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$3M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$0M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$0M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M

    Insider activity

    Net buying14 buys · 0 sellsnet $344K5 insiders · last 365d
    • Middleton Fred ADirector, 10% owner · Common StockBought 248 972 @ $0,80$200K · 2026-06-25
    • Leheny A. RachelDirector, CHIEF EXECUTIVE OFFICER, 10% owner · Common StockOther 186 729 @ $0,80$150K · 2026-06-25
    • WILSON ROBERT NDirector · Common StockOther 1 182 621 @ $0,80$950K · 2026-06-25
    • Hebbar SudarshanChief Medical Officer · Common StockOther 124 486 @ $0,80$100K · 2026-06-25
    • Roberts Eric WDirector, CHIEF BUSINESS OFFICER, 10% owner · Common StockOther 186 729 @ $0,80$150K · 2026-06-25
    • Roberts Eric WDirector, CHIEF BUSINESS OFFICER, 10% owner · Common StockBought 2 500 @ $3,07$8K · 2025-09-18
    • Roberts Eric WDirector, CHIEF BUSINESS OFFICER, 10% owner · Common StockBought 3 400 @ $2,68$9K · 2025-09-15
    • Roberts Eric WDirector, CHIEF BUSINESS OFFICER, 10% owner · Common StockBought 5 000 @ $3,12$16K · 2025-09-12
    • Roberts Eric WDirector, CHIEF BUSINESS OFFICER, 10% owner · Common StockBought 2 343 @ $3,15$7K · 2025-09-09
    • Roberts Eric WDirector, CHIEF BUSINESS OFFICER, 10% owner · Common StockBought 800 @ $2,74$2K · 2025-08-29
    • Roberts Eric WDirector, CHIEF BUSINESS OFFICER, 10% owner · Common StockBought 9 200 @ $2,86$26K · 2025-08-28
    • Roberts Eric WDirector, CHIEF BUSINESS OFFICER, 10% owner · Common StockBought 3 508 @ $2,79$10K · 2025-08-21
    • Roberts Eric WDirector, CHIEF BUSINESS OFFICER, 10% owner · Common StockBought 2 000 @ $2,72$5K · 2025-08-20
    • Roberts Eric WDirector, CHIEF BUSINESS OFFICER, 10% owner · Common StockOther 15 000 @ $1,53$23K · 2025-08-20
    • Roberts Eric WDirector, CHIEF BUSINESS OFFICER, 10% owner · Common StockBought 1 000 @ $2,79$3K · 2025-08-19
    • Hebbar SudarshanChief Medical Officer · Common StockBought 9 563 @ $2,82$27K · 2025-08-19
    • Roberts Eric WDirector, CHIEF BUSINESS OFFICER, 10% owner · Common StockBought 5 076 @ $2,90$15K · 2025-08-15
    • Hebbar SudarshanChief Medical Officer · Common StockBought 4 392 @ $2,79$12K · 2025-08-15
    • Hebbar SudarshanChief Medical Officer · Common StockBought 1 584 @ $2,58$4K · 2025-08-14

    Short positioning

    960.7Kshares short-41.8% vs prior
    2.36days to cover
    54.0%short of daily vol
    33.6Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    CALCCanonical
    Nasdaq · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    What changed

    no material change vs prior analysis (walked 17 fields; 4 schema-expansion field(s) excluded)

    • Narrative— → —medium
    • Conclusion— → —medium
    • Key takeaways— → —medium
    vs prior analysis today
    peak dispatch · —
    OSINT findings
    Dilution riskHigh
    Liquidity riskHigh
    Diluted share count is moderately above the basic share count.
    Filings reference going-concern or substantial-doubt language.
    Source documents mention dilution or offering risk.

    Evidence & claims

    From filings & derived data
    • EPS (diluted) (annual): USD-PER-SHARES -2Unknown
    • Shareholders' equity (annual): USD -6.64MUnknown
    • Capex (annual): USD 28KUnknown
    • Pre-tax income (annual): USD -29.56MUnknown
    • Operating income (annual): USD -23.12MUnknown
    • EPS (basic) (annual): USD-PER-SHARES -2Unknown
    • Cash & equivalents (annual): USD 11.52MUnknown
    • Total assets (annual): USD 13.59MUnknown
    • Operating cash flow (annual): USD -21.18MUnknown
    • Total liabilities (annual): USD 20.23MUnknown
    • Shares outstanding (annual): 15.44MUnknown
    • Current liabilities (annual): USD 3.78MUnknown
    • R&D expense (annual): USD 15.23MUnknown
    • Current assets (annual): USD 13.53MUnknown
    • Net income (annual): USD -29.56MUnknown
    • Total operating expenses (annual): USD 23.12MUnknown
    • Capex (annual): USD 8KUnknown
    • Current assets (annual): USD 19.66MUnknown
    • Total liabilities (annual): USD 5.38MUnknown
    • EPS (diluted) (annual): USD-PER-SHARES -1Unknown
    • Total operating expenses (annual): USD 24.2MUnknown
    • Cash & equivalents (annual): USD 7.93MUnknown
    • R&D expense (annual): USD 14.48MUnknown
    • Shares outstanding (annual): 13.48MUnknown
    Showing 24 of 32 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-08-01 22:30 UTCEVENTHa Price Listing CALC approaching NASDAQ minimum-bid deficiency: closed below $1.00 for 21 consecutive trading days (deficiency at 30). Last close $0.9401.
    2026-08-01 21:54 UTCEVENTHa Price Move CALC extraordinary up move (8.682% 1d, 1.19x sigma) on x1.948 volume
    2026-07-08 04:39 UTCFILINGMaterial 8-K
    2026-07-02INSIDERZaytsev Evgeny acquired 20.0k sh Director Stock Option (Right to Buy) — Director
    2026-06-25 00:00 UTCINSIDER5 insider transactions — 2026-06 · net buy $1.5M
    2026-06-25INSIDERHebbar Sudarshan transacted 124.5k sh — Chief Medical Officer ~$100k
    2026-06-25INSIDERLeheny A. Rachel transacted 186.7k sh — Director, CHIEF EXECUTIVE OFFICER, 10% owner ~$150k
    2026-06-25INSIDERWILSON ROBERT N transacted 1.18M sh — Director ~$950k
    2026-06-25INSIDERMiddleton Fred A bought 249.0k sh — Director, 10% owner ~$200k
    2026-06-25INSIDERRoberts Eric W transacted 186.7k sh — Director, CHIEF BUSINESS OFFICER, 10% owner ~$150k
    2026-05-12FILING10-Q filing →
    2026-05-12FILING8-K filing →
    2026-03-31EARNINGSQuarterly results — Q4 2025 Net USD 5.0M
    2026-03-18FILING8-K filing →
    2026-03-03FILING10-K filing →
    2026-03-03FILING8-K filing →
    2026-01-28FILING8-K filing →
    2026-01-28FILING8-K filing →
    2025-12-31EARNINGSQuarterly results — Q3 2025
    2025-12-31EARNINGSAnnual results — FY 2025 Net USD -29.6M
    2025-11-12FILING10-Q filing →
    2025-11-12FILING8-K filing →
    2025-11-06FILING8-K filing →
    2025-11-06FILING424B5 filing →
    2025-10-13 00:00 UTCINSIDER1 insider transaction — 2025-10 1 derivative
    2025-10-13INSIDERGlicklich Alan acquired 937 sh Director Stock Option (Right to Buy) — Director
    2025-09-30EARNINGSQuarterly results — Q2 2025 Net USD -18.8M
    2025-09-18 00:00 UTCINSIDER4 insider transactions — 2025-09
    2025-09-18INSIDERRoberts Eric W bought 2.5k sh — Director, CHIEF BUSINESS OFFICER, 10% owner ~$8k
    2025-09-15INSIDERRoberts Eric W bought 3.4k sh — Director, CHIEF BUSINESS OFFICER, 10% owner ~$9k
    2025-09-12INSIDERRoberts Eric W bought 5.0k sh — Director, CHIEF BUSINESS OFFICER, 10% owner ~$16k
    2025-09-09INSIDERRoberts Eric W bought 2.3k sh — Director, CHIEF BUSINESS OFFICER, 10% owner ~$7k
    2025-08-29 00:00 UTCINSIDER11 insider transactions — 2025-08 · net buy $128k 1 derivative
    2025-08-29INSIDERRoberts Eric W bought 800 sh — Director, CHIEF BUSINESS OFFICER, 10% owner ~$2k
    2025-08-28INSIDERRoberts Eric W bought 9.2k sh — Director, CHIEF BUSINESS OFFICER, 10% owner ~$26k
    2025-08-21INSIDERRoberts Eric W bought 3.5k sh — Director, CHIEF BUSINESS OFFICER, 10% owner ~$10k
    2025-08-20INSIDERRoberts Eric W bought 2.0k sh — Director, CHIEF BUSINESS OFFICER, 10% owner ~$5k
    2025-08-20INSIDERRoberts Eric W transacted 15.0k sh — Director, CHIEF BUSINESS OFFICER, 10% owner ~$23k
    2025-08-20INSIDERRoberts Eric W disposed of 15.0k sh Employee Stock Option (Right to Buy) — Director, CHIEF BUSINESS OFFICER, 10% owner
    Showing the 40 most recent of 51 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage